Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced inducement grants to eight new employees under its 2024 Inducement Plan. The grants include non-qualified stock options to purchase 85,000 shares of Class A common stock at $21.90 per share and restricted stock units (RSUs) for 45,250 shares.

The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting from either August 20 or November 20, 2025. All grants are subject to continued employment with Vera.

News Market Reaction

+2.32%

48 alerts

+2.32% News Effect

+7.0% Peak in 4 hr 36 min

+$36M Valuation Impact

$1.57B Market Cap

1.1x Rel. Volume

On the day this news was published, VERA gained 2.32%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.0% during that session. Our momentum scanner triggered 48 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $36M to the company's valuation, bringing the market cap to $1.57B at that time.

Data tracked by StockTitan Argus on the day of publication.

BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 85,000 shares of Class A common stock and restricted stock units (RSUs) underlying 45,250 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on September 4, 2025 has an exercise price per share equal to $21.90, Vera’s closing trading price on September 4, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of either August 20 or November 20, 2025, depending on the start date of the new employee, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.

For more information, please contact: Investor Contact:
Joyce Allaire
LifeSci Advisors 212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth Vera Therapeutics 415-854-8051
corporatecommunications@veratx.com

FAQ

What inducement grants did Vera Therapeutics (VERA) announce on September 5, 2025?

Vera announced stock options for 85,000 shares at $21.90 per share and RSUs for 45,250 shares of Class A common stock to eight new employees.

What is the vesting schedule for Vera Therapeutics' (VERA) new stock options?

The stock options vest over 4 years, with 25% vesting after the first year and the remaining shares vesting monthly over 36 months.

How will the RSUs vest for Vera Therapeutics' (VERA) new employees?

The RSUs vest over 4 years, with 25% vesting annually on either August 20 or November 20, 2025, depending on the employee's start date.

What is the exercise price for VERA's newly granted stock options?

The stock options have an exercise price of $21.90 per share, which was Vera's closing trading price on September 4, 2025.